IP Library › Granted Patent US 12,451,250
Granted Patent B2
US 12,451,250 · App. 17/771,401 · Granted Oct 21, 2025

Systems and methods for predicting therapeutic sensitivity

Inventors: Ameen Salahudeen (Oak Park, IL); Brian M. Larsen (Chicago, IL); Michelle M. Stein (Morton Grove, IL); Luka A. Karginov (Westmont, IL); Madhavi Kannan (Chicago, IL); Aly A. Khan (Chicago, IL); Verónica Sánchez Freire (Chicago, IL); Yilin Zhang (Wilmette, IL)
Assignee: Tempus AI, Inc.
G16H50/20G16B40/20
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,451,250
App. No.
17/771,401
Granted
Oct 21, 2025
Kind
B2
Abstract

Methods, systems, and software are provided for using organoid cultures, e.g., patient-derived tumor organoid cultures, to improve treatment predictions and outcomes.

Claims (30)

1. A method for training a classifier to discriminate between two or more tumor sensitivities to a poly ADP ribose polymerase (PARP) inhibitor, the method comprising:

(A) obtaining, for each respective tissue sample in a plurality of tissue samples, a corresponding plurality of nucleic acid features of the respective tissue sample;

(B) obtaining, for each respective tissue sample in the plurality of tissue samples, a corresponding indication of the sensitivity of a respective one or more organoids cultured from one or more cells of the respective tissue sample to the PARP inhibitor; and at a computer system comprising at least one processor and a memory storing at least one program for execution by the at least one processor:

(C) training an untrained classifier against at least (i) the corresponding plurality of nucleic acid features and (ii) the corresponding indication of the sensitivity of the respective one or more organoids to the PARP inhibitor, across the plurality of tissue samples, thereby obtaining a trained classifier that discriminates between the two or more tumor sensitivities to the PARP inhibitor wherein

a first tumor sensitivity in the two or more tumor sensitivities to the PARP inhibitor is associated with an indication of resistance to the PARP inhibitor, and

a second tumor sensitivity in the two or more tumor sensitivities to the PARP inhibitor is associated with an indication of absence of resistance to the PARP inhibitor.

2. The method of claim 1 , wherein the PARP inhibitor is selected from the group consisting of olaparib, veliparib, rucaparib, niraparib, and talazoparib.

3. The method of claim 1 , wherein the classifier is further trained to discriminate between the two or more tumor sensitivities to the PARP inhibitor and one or more tumor sensitivities to a chemotherapeutic drug that is not a PARP inhibitor.

4. The method of claim 1 , wherein each tissue sample in the plurality of tissue samples comprises a breast cancer biopsy.

5. The method of claim 1 , wherein each tissue sample in the plurality of tissue samples comprises an ovarian cancer biopsy.

6. The method of claim 1 , wherein each tissue sample in the plurality of tissue samples comprises a biopsy of a homologous recombination deficient (HRD) cancer.

7. The method of claim 1 , wherein each tissue sample in the plurality of tissue samples comprises a biopsy from a cancer other than breast cancer or ovarian cancer.

8. The method of claim 1 , wherein the plurality of nucleic acid features of the tissue sample comprises one or more of an indication of a presence of a single nucleotide variant at a genomic location, a methylation status at a genomic location, a relative copy number for a genomic location, an allelic ratio for a genomic location, a relative expression level of a gene, and mathematical combinations thereof.

9. The method of claim 8 , wherein the plurality of nucleic acid features of the tissue sample comprises a BRCA1 or BRCA2 mutant allele status.

10. The method of claim 1 , wherein at least a sub-plurality of the plurality of nucleic acid features of the respective tissue sample are measured from the respective one or more organoids cultured from one or more cells of the respective tissue sample.

11. The method of claim 1 , wherein the indication of the sensitivity of the respective one or more organoids to the PARP inhibitor is based at least in part on one or more cellular fitness measurements obtained by:

i) exposing the respective one or more organoids to one or more amounts of the PARP inhibitor; and

ii) measuring the fitness of cells in the respective one or more organoids following the exposure to the one or more amounts of the PARP inhibitor, thereby obtaining the one or more cellular fitness measurements.

12. The method of claim 11 , wherein the one or more cellular fitness measurements are one or more measurements of cellular apoptosis following exposure to the one or more amounts of the PARP inhibitor.

13. The method of claim 12 , wherein, for at least one respective tissue sample in the plurality of tissue samples, the respective one or more organoids are exposed to a sensitizing therapy before being exposed to the PARP inhibitor.

14. The method of claim 1 , wherein the untrained classifier is further trained against, for each respective tissue sample in the plurality of tissue samples, (iii) a corresponding cancer classification of the tissue sample in a plurality of cancer classifications.

15. The method of claim 14 , wherein the plurality of cancer classifications comprises cancerous tissue and non-cancerous tissue.

16. The method of claim 14 , wherein the plurality of cancer classifications comprises a plurality of types of cancer.

17. The method of claim 14 , wherein the plurality of cancer classifications comprises a plurality of stages of a cancer.

18. The method of claim 1 , wherein: the plurality of tissue samples comprises a plurality of tumor biopsies; and the training (C) comprises identifying a plurality of genes that are differentially expressed between (i) organoids, cultured from one or more cells of a respective tumor biopsy in the plurality of tumor biopsies, that have the first tumor sensitivity to the PARP inhibitor, and (ii) organoids, cultured from one or more cells of a respective tumor biopsy in the plurality of tumor biopsies, that have the second tumor sensitivity to the PARP inhibitor.

19. The method of claim 1 , wherein the untrained classifier is further trained against, for each respective tissue sample in the plurality of tissue samples, (iv) one or more phenotypic characteristics of the respective tissue sample.

20. The method of claim 19 , wherein the one or more phenotypic characteristics of the tissue sample comprise a histologic feature of the tissue sample.

21. The method of claim 1 , wherein the untrained classifier is further trained against, for each respective tissue sample in the plurality of tissue samples, (v) one or more characteristics of the subject from which the tissue sample was obtained.

22. The method of claim 1 , wherein the classifier is a multinomial classifier that is trained to provide a plurality of likelihoods, wherein each respective likelihood in the plurality of likelihoods is a likelihood that tumor cells from a test subject with cancer will have a different respective sensitivity in the two or more tumor sensitivities to a PARP inhibitor.

23. The method of claim 1 , wherein the trained classifier is a neural network algorithm, a support vector machine algorithm, a Naive Bayes algorithm, a nearest neighbor algorithm, a boosted trees algorithm, a random forest algorithm, a convolutional neural network algorithm, a decision tree algorithm, a regression algorithm, or a clustering algorithm.

Assignments (5)
RELEASE OF SECURITY INTEREST Recorded May 13, 2026
From: ARES CAPITAL CORPORATION, AS COLLATERAL AGENT
To: TEMPUS AI, INC. (F/K/A TEMPUS LABS, INC.)
Reel/Frame 075608/0784 →
CHANGE OF NAME Recorded Feb 29, 2024
From: TEMPUS LABS, INC.
To: TEMPUS AI, INC.
Reel/Frame 066707/0382 →
SECURITY INTEREST Recorded Sep 22, 2022
From: TEMPUS LABS, INC.
To: ARES CAPITAL CORPORATION, AS COLLATERAL AGENT
Reel/Frame 061506/0316 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 26, 2022
From: SALAHUDEEN, AMEEN
To: TEMPUS LABS, INC.
Reel/Frame 059737/0162 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 26, 2022
From: LARSEN, BRIAN M.; STEIN, MICHELLE M.; KARGINOV, LUKA A.; SALAHUDEEN, AMEEN; KANNAN, MADHAVI; KHAN, ALY A.; SÁNCHEZ FREIRE, VERÓNICA; ZHANG, YILIN
To: TEMPUS LABS, INC.
Reel/Frame 059740/0218 →
Continuity (3)
Provisional Application 62944292 · Dec 5, 2019
Provisional Application 62924621 · Oct 22, 2019
Related Publication 20220392640A1 · Dec 8, 2022
References Cited (147)
US 11043304B2 · Lozac'hmeur · 2021 [cited by examiner]
US 20100158330A1 · Guissin · 2010 [cited by applicant]
US 20120200694A1 · Garsha · 2012 [cited by applicant]
US 20120200695A1 · Yamane · 2012 [cited by applicant]
US 20150329829A1 · Shen et al. · 2015 [cited by applicant]
US 20170336392A1 · Theodorakis · 2017 [cited by applicant]
US 20190065905A1 · Raphaeli · 2019 [cited by applicant]
US 20200211716A1 · Lefkofsky · 2020 [cited by applicant]
US 20200365232A1 · Jaros · 2020 [cited by applicant]
US 20200381087A1 · Ozeran · 2020 [cited by applicant]
US 20210090694A1 · Colley · 2021 [cited by applicant]
US 20210155989A1 · Salahudeen · 2021 [cited by applicant]
EP 2412800A1 · 2012 [cited by applicant]
EP 2743345A1 · 2014 [cited by applicant]
WO WO2009022907A2 · 2009 [cited by applicant]
WO WO2010090513A2 · 2010 [cited by applicant]
WO WO2012014076A2 · 2012 [cited by applicant]
WO WO2012168930A2 · 2012 [cited by applicant]
WO WO2013093812A2 · 2013 [cited by applicant]
WO WO2014159356A1 · 2014 [cited by applicant]
WO WO2015173425A1 · 2015 [cited by applicant]
WO WO2016083612A1 · 2016 [cited by applicant]
WO WO2016083613A2 · 2016 [cited by applicant]
WO WO2017149025A1 · 2017 [cited by applicant]
WO WO2017220586A1 · 2017 [cited by applicant]
WO WO2019018693A2 · 2019 [cited by applicant]
WO WO2019035766A1 · 2019 [cited by applicant]
WO WO2019094230A1 · 2019 [cited by applicant]
WO WO2019152767A1 · 2019 [cited by applicant]
WO WO2020168008A1 · 2020 [cited by applicant]
Barazas et al., “Radiosensitivity is an Acquired Vulnerability of PARPi-Resistant BRCA1-Deficient Tumors”, Cancer Research, 79(3), Feb. 1, 2019, pp. 10. [cited by applicant]
Duarte et al., BRCA-deficient mouse mammary tumor organoids to study cancer-drug resistance, Nature Methods, vol. 15, No. 2, Feb. 2018, pp. 13. [cited by applicant]
Supplementary Information for Li, X. et al., Nature Communications vol. 9, Article No. 2983 (Jul. 30, 2018), online at https://www.nature.com/articles/s41467-018-05190-9#Sec26, 11 printed pages. (Year: 2018). [cited by applicant]
Supplementary Materials for “Patient-derived organoids model treatment response of metastatic gastrointestinal cancers” (V published Feb. 23, 2018, Science 359, 920) from https ://science .sciencemag.org/content/suppl/2… [cited by applicant]
Yancovitz, M. et al. “Intra- and Inter-Tumor Heterogeneity of BRAFV600E Mutations in Primary and Metastatic Melanoma” PLoS One, Jan., 2012, vol. 7, issue 1 (Year: 2012). [cited by applicant]
Ou, S.-H. I. et al. “Liquid Biopsy to Identify Actionable Genomic Alterations” American Society of Clinical Oncology Educational Book 38 (May 23, 2018) 978-997 (Year: 2018). [cited by applicant]
Bronkhorst, A.J. et al. “Characterization of the cell-free DNA released by cultured cancer cells”, Biochimica et Biophysica Acta 1863 (2016) 157-165 (Year: 2016). [cited by applicant]
Li, X. et al. “Organoid cultures recapitulate esophageal adenocarcinoma heterogeneity providing a model for clonality studies and precision therapeutics” Nature Communications, (2018) 9:2983, pp. 1-11 (Year: 2018). [cited by applicant]
Eke et al. “Radiobiology goes 3D: How ECM and cell morphology impact on cell survival after irradiation”, Radiotherapy and Oncology, vol. 99, pp. 271-278 (2011). [cited by applicant]
Breslin et al. “Three-dimensional cell culture: the missing link in drug discovery”, Drug Discovery Today, vol. 18, Nos. 5/6 (2013). [cited by applicant]
Driehuis et al. “Oral Mucosal Organoids as a Potential Platform for Personalized Cancer Therapy”, Cancer Discovery, vol. 9, pp. 852-871 (2019). [cited by applicant]
Tuveson et al. “Cancer modeling meets human organoid technology”, Science, vol. 364, pp. 952-955 (2019). [cited by applicant]
Eder et al. :3D Hanging Drop Culture to Establish Prostate Cancer Organoids, 3D Cell Culture: Methods and Protocols, Methods in Molecular Biology, vol. 1612, pp. 167-175. [cited by applicant]
Andor et al. “Pan-cancer analysis of the extent and consequences of intra-tumor heterogeneity”, Nat Med., vol. 22, pp. 105-113 (2016). [cited by applicant]
Bein et al. “Microfluidic Organ-on-a-Chip models of Human Intestine”, Cellular and Molecular Gastroenterology and Heptatology, vol. 5, No. 4, pp. 659-668 (2018). [cited by applicant]
Ben-David et al. “Genetic and Transcriptional evolution alters cancer cell line drug response”, Nature, vol. 560, pp. 325-330 (2018). [cited by applicant]
Boj et al. “Organoid Models of Human and Mouse Ductal Pancreatic Cancer”, Cell, vol. 160, pp. 324-338 (2015). [cited by applicant]
Bozic et al. “Timing and heterogeneity of mutations associated with drug resistance in metastic cancers” PNAS, vol. 111, No. 45, pp. 15964-15968 (2014). [cited by applicant]
Brayer et al. “Recurrent Fusions in MYB and MYBL1 Define a Common, Transcription Factor-Driven Oncogenic Pathway in Salivary Gland Adenoid Cystic Carcinoma” Cancer Discov., vol. 6, pp. 176-187 (2016). [cited by applicant]
Broutier et al. “Human Primary Liver Cancer-derived Organoid Cultures for disease modelling and drug screening” Nat. Med., vol. 23, pp. 1424-1435 (2017). [cited by applicant]
Pflug et al. “TRUmiCount: correctly counting absolute Nos. of molecules using unique molecular identifiers”, Bioinformatics, vol. 24, pp. 3137-3144 (2018). [cited by applicant]
Chomczynski et al. “The single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction: twenty-something years on”, Nature Protocols, vol. 1, No. 2, pp. 581-585 (2006). [cited by applicant]
Chowell et al. “When (distant) relatives stay too long: implications for cancer medicine”, Genome Biology, vol. 17, pp. 1-3 (2016). [cited by applicant]
Rio et al. “Enrichment of Poly(A) mRNA Using Immobilized Oligo(dT)”, Cold Spring Harbor Laboratory Press, vol. 2010, Issue 7, pp. 1-3 (2010). [cited by applicant]
Mootha et al. “PGC-1α-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes”, Nature genetics, vol. 34, pp. 267-273 (2003). [cited by applicant]
Burgess et al. “RNA extraction from self-assembling peptide hydrogels to allow qPCR analysis of encapsulated cells” Plos One, pp. 1-19, (2018). [cited by applicant]
De Lau et al. “The R-spondin protein family”, Genome Biology, vol. 13, pp. 1-10 (2012). [cited by applicant]
Ozsolak et al. “Direct RNA sequencing”, Nature, vol. 461, pp. 814-818 (2009). [cited by applicant]
Finotello et al. “Measuring differential gene expression with RNA-seq: challenges and strategies for data analysis”, Briefings in Functional Genomics, vol. 14, pp. 130-142 (2014). [cited by applicant]
Ganesh et al. “A rectal cancer organoid platform to study individual responses to chemoradiation”, Nature Medicine. [cited by applicant]
Gao et al. “Organoid cultures derived from patients with advanced prostate cancer”, Cell, vol. 159, pp. 176-187 (2014). [cited by applicant]
Goodspeed et al. “Tumor-Derived Cell Lines as Molecular Models of Cancer Pharmacogenomics”, Mol. Cancer. Res., vol. 14, pp. 3-13 (2016). [cited by applicant]
Gramont et al. “Novel TGF-β inhibitors ready for prime time in onco-immunology”, Oncoimmunology, vol. 6, pp. e1257453 (2017). [cited by applicant]
Jabs et al. “Screening drug effects in patient-derived cancer cells links organoid responses to genome alterations”, Mol. Systems Biology, vol. 13, pp. 1-16 (2017). [cited by applicant]
Kivioja et al. “Counting absolute nuymbers of molecules using unique molecular identifiers”, Nature Methods, vol. 9, No. 1, pp. 72-74 (2012). [cited by applicant]
Landau et al. “Evolution and impact of subclonal mutations in chronic lymphocytic leukemia”, Cell, vol. 152, pp. 714-726 (2013). [cited by applicant]
Lee et al. “Tumor evolution and drug response in patient-derived organoid models of bladder cancer”, Cell, vol. 173, pp. 515-528 (2018). [cited by applicant]
Lin et al. “mRNA/cDNA Library Construction Using RNA-Polymerase Cycling Reaction”, Methods in Molecular Biology, vol. 221, pp. 129-143. [cited by applicant]
Liu et al. “The Cross-contaminated Cell Lines of Adenoid Cystic Carcinoma: A Crucial Concern”, Translational Surgery, vol. 2, pp. 10-13 (2017). [cited by applicant]
Maley et al. “Genetic clonal diversity predicts progression to esophageal adenocarcinoma”, Nature Genetics, vol. 38, pp. 468-473 (2006). [cited by applicant]
McConnell et al. “Construction of a representative cDNA library from mRNA isolated from mouse oocytes”, FEBS, vol. 195, pp. 199-202 (1986. [cited by applicant]
McCunE and Grace “Distance Measures”, Chapter 6, pp. 45-57 (2002). [cited by applicant]
Yan et al. “A Comprehensive Human Gastric Cancer Organoid Biobank Captures Tumor Subtype Heterogeneity and Enables Therapeutic Screening”, Cell Stem Cell, vol. 23, pp. 882-897 (2018). [cited by applicant]
Nagalakshmi et al. “The Transcriptional Landscape of the Yeast Genome Defined by RNA Sequencing”, Science, vol. 320, pp. 1344-1349 (2008). [cited by applicant]
Nagle et al. “Patient-derived tumor organoids for prediction of cancer treatment response”, Seminars in Cancer Biology, vol. 15, pp. 258-264 (2018). [cited by applicant]
Neal, James T., et al. “Organoid Modeling of the Tumor Immune Microenvironment”, Cell 175, 2018, pp. 1972-1988. [cited by applicant]
Shendure et al. “Next-generation DNA sequencing”, Nature Biotechnology, vol. 26, pp. 1135-1145 (2008). [cited by applicant]
Niederst et al. “Bypass Mechanisms of Resistance to Receptor Tyrosine Kinase Inhibition in Lung Cancer”, Sci Signal, vol. 6, pp. 1-12 (2014). [cited by applicant]
Garalde et al. “Highly parallel direct RNA sequencing on an array of nanopores”, Nature Methods, vol. 15, pp. [cited by applicant]
Oh et al. “An improved method for constructing a full-length enriched cDNA library using small amounts of total RNA as a starting material”, Experimental and Molecular Medicine, vol. 35, pp. 586-590 (2003). [cited by applicant]
Ooft et al. “Patient-derived organoids can predict response to chemotherapy in metastatic colorectal cancer patients”, Science Translational Medicine, vol. 11, pp. 1-9 (2019). [cited by applicant]
Pereira et al. “The somatic mutation profiles of 2,433 breast cancers refines their genomic and transcriptomic landscapes”, Nature Communications, vol. 7, pp. 1-15 (2016). [cited by applicant]
Poeckh et al. “Adsorption and elution characteristics of nucleic acids on silica surfaces and their use in designing a miniaturized purification unit”, Anal. Biochem., vol. 15, pp. 253-262 (2008). [cited by applicant]
Puca et al. “Patient derived organoids to model rare prostate cancer phenotypes”, Nature Communications, vol. 9, pp. 1-10 (2018). [cited by applicant]
Duda et al. “Pattern Classification”, Second Edition, 735 pages. [cited by applicant]
Drost et al. “Organoids in cancer research”, Nature Reviews, vol. 18, pp. 407-418 (2018). [cited by applicant]
Sachs et al. “A Living Biobank of Breast Cancer Organoids Captures Disease Heterogeneity”, Cell, vol. 172, pp. 373-386 (2018). [cited by applicant]
Fujii et al. “A Colorectal Tumor Organoid Library Demonstrates Progressive Loss of Niche Factor Requirements during Tumorigenesis”, Cell Stem Cell, vol. 18, pp. 827-838 (2016). [cited by applicant]
Serrati et al. “Next-generation sequencing: advances and applications in cancer diagnosis”. OncoTargets and Therapy, vol. 9, pp. 7355-7365 (2016). [cited by applicant]
Subramanian et al. “Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles”, PNAS, vol. 102, No. 43, pp. 15545-15550 (2005). [cited by applicant]
Islam et al. “Quantitative single-cell RNA-seq with unique molecular identifiers”, Nature Methods, vol. 11, No. 2, pp. 163-166 (2014). [cited by applicant]
Urbischek et al. “Organoid culture media formulated with growth factors of defined cellular activity”, Scientific Reports, vol. 9, pp. 1-11 (2019). [cited by applicant]
Van De Wetering et al. “Prospective derivation of a Living Organoid Biobank of colorectal cancer patients”, Cell, vol. 161, pp. 933-945 (2015). [cited by applicant]
Vlachogiannis et al. “Patient-derived organoids model treatment response of metastatic gastrointestinal cancers”, Science, vol. 359, pp. 920-926 (2018). [cited by applicant]
Wang et al. “RNA-Seq: a revolutionary tool for transcriptomics”, Nat Rev Genet., vol. 10, pp. 57-63 (2009). [cited by applicant]
Xu et al. “Organoid technology and applications in cancer research”, Journal of Hematology & Oncology, vol. 11, pp. 1-15 (2018). [cited by applicant]
Yao et al. “Patient-Derived Organoids Predict Chemoradiation Responses of Locally Advanced Rectal Cancer”, Cell Press, vol. 26, pp. 1-10 (2020). [cited by applicant]
Zhang et al. “Intra-tumor Heterogeneity in Localized Lung Adenocarcinomas Delineated by Multi-region Sequencing”, Science, vol. 346, pp. 256-259 (2014). [cited by applicant]
Korenchuk et al. “VCaP, A Cell-Based Model System of Human Prostate Cancer”, In Vivo, vol. 15, pp. 163-168 (2001). [cited by applicant]
Cardea's Tech+Bio Infrastructure, Cardea Bio | Graphene-based, Biology-gated Transistor Technology, https://cardeabio.com/technology/, 4 pages. [cited by applicant]
Ashford, Molika, “Harvard Team Advancing Algorithmic Signature to Improve PARP Inhibitor Patient Selection”, genomeweb, Apr. 18, 2019, 3 pages. [cited by applicant]
Brenan, Lisa, et al. “Phenotypic characterization of a comprehensive set of MAPK1/ERK2 missense mutants”, Cell Rep., Oct. 18, 2016, 23 pages. [cited by applicant]
Dijkstra, Krijn K., et al. “Generation of Tumor-Reactive T Cells by Co-culture of Peripheral Blood Lymphocytes and Tumor Organoids”, CellPress, Sep. 6, 2018, Cell 174, pp. 1586-1598. [cited by applicant]
Findlay, Gregory M., et al. “Saturation Editing of Genomic Regions by Multiplex Homology-Directed Repair”, Nature, Sep. 4, 2014, 24 pages. [cited by applicant]
Findlay, Gregory M., et al. “Accurate classification of BRCA1 variants with saturation genome editing”, Nature, Oct. 2018, 32 pages. [cited by applicant]
Giacomelli, Andrew O., et al. “Mutational processes shape the landscape of TP53 mutations in human cancer”, Nat Genet, Oct. 2018, 20 pages. [cited by applicant]
Gulhan, Doga C., et al. “Detecting the mutational signature of homologous recombination deficiency in clinical samples”, Technical Report, Nature Genetics, vol. 51, May 2019, pp. 912-919. [cited by applicant]
Jenkins, et al. “Ex Vivo Profiling of PD-1 Blockade Using Organotypic Tumor Spheroids”, Cancer Discov., Feb. 2018, 36 pages. [cited by applicant]
Kohsaka, Shinji, et al. “A method of high-throughput functional evaluation of EGFR gene variants of unknown significance in cancer”, Science Translational Medicine | Research Resource, Med. 9, Nov. 15, 2017, 12 pages. [cited by applicant]
Matsumoto, N. et al. “C3a Enhances the Formation of Intestinal Organoids through C3aR1” Frontiers in Immunology, Sep. 4, 2017, vol. 8:1046 (Year 2017). [cited by applicant]
Matreyek, Kenneth A., et al. “Multiplex Assessment of Protein Variant Abundance by Massively Parallel Sequencing”, Nat Genet., Jun. 2018, 27 pages. [cited by applicant]
Mighell, Taylor L., et al. “A Saturation Mutagenesis Approach to Understanding PTEN Lipid Phosphatase Activity and Genotype-Phenotype Relationships”, The American Journal of Human Genetics 102, May 3, 2018, pp. 943-955. [cited by applicant]
Nam, M.-O. et al. “Effects of a small molecule R-spondin-1 substitute RS-246204 on a mouse intestinal organoid culture” Oncotarget, 2018, vol. 9, (No. 5), pp. 6356-6368 (Published: Dec. 26, 2017). (Year 2017). [cited by applicant]
Sato, Toshiro, et al. “Single Lgr5 stem cells build crypt-villus structures in vitro without a mesenchymal niche”, Nature, vol. 459, May 14, 2009, pp. 262-265. [cited by applicant]
Sato, Toshiro, et al. “Long-term Expansion of Epithelial Organoids From Human Colon, Adenoma, Adenocarcinoma, and Barrett's Epithelium”, Gastroenterology, vol. 141, No. 5, Nov. 2011, pp. 1762-1772. [cited by applicant]
Celli et al., “An Imaging-based platform for high-content, quantitative evaluation of therapeutic response in 3D tumour models”, Scientific Reports, vol. 4 (3751), published Jan. 17, 2014, pp. 1-10. [cited by applicant]
Liu et al., “Automated Counting of Cancer Cells by Ensembling Deep Features”, Cells, vol. 8 (1019), published Sep. 2, 2019, pp. 1-14. [cited by applicant]
Bailo, O. et al. “Red blood cell image generation for data augmentation using conditional generative adversarial networks.” Proceedings of the IEEE/CVF Conference on Computer Vision and Pattern Recognition Workshops. 20… [cited by applicant]
Brunet, D., et al. “On the mathematical properties of the structural similarity index.” IEEE Transactions on Image Processing 21.4 (2012): 1488-1499. [cited by applicant]
Ihle, S., et al. “UDCT: Unsupervised data to content transformation with histogram-matching cycle- consistent generative adversarial networks.” bioRxiv (2019): 563734. [cited by applicant]
Ouyang, W., et al. “Deep learning massively accelerates super-resolution localization microscopy.” Nature biotechnology 36.5 (2018): 460-468. [cited by applicant]
Renieblas, G. P., et al. “Structural similarity index family for image quality assessment in radiological images.” Journal of medical imaging 4.3 (2017): 035501. [cited by applicant]
Rivenson, Y., et al. “Virtual histological staining of unlabelled tissue-autofluorescence images via deep learning.” Nature biomedical engineering 3.6 (2019): 466-477. [cited by applicant]
Sampat, M. P., et al. “Complex wavelet structural similarity: A new image similarity index.” IEEE transactions on image processing 18.11 (2009): 2385-2401. [cited by applicant]
Tsuda, H. et al. “Cell image segmentation by integrating pix2pixs for each class.” Proceedings of the IEEE/CVF Conference on Computer Vision and Pattern Recognition Workshops. 2019. [cited by applicant]
Wang, Z., et al. “Image quality assessment: from error visibility to structural similarity.” IEEE transactions on image processing 13.4 (2004): 600-612. [cited by applicant]
Zhu, J.-Y., et al. “Unpaired Image-to-Image Translation using Cycle-Consistent Adversarial Networks.” arXiv preprint arXiv:1703.10593 (2017). [cited by applicant]
Business Wire. Recursion Pharmaceuticals Announces Research Agreement With Sanofi Genzyme. Apr. 25, 2016. Version accessed Apr. 26, 2016. Available online at https://www.businesswire.com/news/home/20160425005113/en/Recu… [cited by applicant]
Christiansen, Eric M., et al. “In silico labeling: predicting fluorescent labels in unlabeled images.” Cell 173.3 (2018): 792-803. [cited by applicant]
El-Melegy, M., et al. “Identification of tuberculosis bacilli in ZN-stained sputum smear images: A deep learning approach.” Proceedings of the IEEE/CVF Conference on Computer Vision and Pattern Recognition Workshops. 20… [cited by applicant]
Fu, C., et al. “Three Dimensional Fluorescence Microscopy Image Synthesis and Segmentation.” arXiv preprint arXiv:1801.07198 (2018). [cited by applicant]
Gilead. Gilead and insitro Announce Strategic Collaboration to Discover and Develop Novel Therapies for Nonalcoholic Steatohepatitis. Press Release. Apr. 16, 2019. Version accessed Jun. 28, 2020. https://web.archive.org… [cited by applicant]
Guo, S.-M., et al. “Revealing architectural order with quantitative label-free imaging and deep neural networks.” BioRxiv (2019): 631101. [cited by applicant]
Han, L. et al. “Transferring microscopy image modalities with conditional generative adversarial networks.” Proceedings of the IEEE Conference on Computer Vision and Pattern Recognition Workshops. 2017. [cited by applicant]
International Searching Authority. International Search Report and Written Opinion for application PCT/US2020/063619. Mailed on Mar. 9, 2021. 11 pages. [cited by applicant]
Isola, P., et al. “Image-to-Image Translation with Conditional Adversarial Networks.” arXiv preprint arXiv:1611.07004 (2016). [cited by applicant]
Kim, D., et al. “AI-powered transmitted light microscopy for functional analysis of live cells.” Scientific reports 9.1 (2019): 1-9. [cited by applicant]
Lee, H.-C., et al. “Enhancing high-content imaging for studying microtubule networks at large-scale.” arXiv preprint arXiv:1910.00662 (2019). [cited by applicant]
Leopold, G. Intel Adds Memory to Deep Learning for Drug Discovery. May 31, 2018. Version accessed Jun. 20, 2020 at https://web.archive.org/web/20200620144314/https://www.datanami.com/2018/05/31/intel-adds-memory-to-deep… [cited by applicant]
Nguyen, T. C., et al. “Virtual organelle self-coding for fluorescence imaging via adversarial learning.” Journal of biomedical optics 25.9 (2020): 096009. [cited by applicant]
Ounkomol, C., et al. “Label-free prediction of three-dimensional fluorescence images from transmitted-light microscopy.” Nature methods 15.11 (2018): 917-920. [cited by applicant]
U.S. Appl. No. 62/924,515, titled “Artificial Intelligence Assisted Precision Medicine Enhancements to Standardized Laboratory Diagnostic Testing”, filed Oct. 22, 2019. [cited by applicant]
U.S. Appl. No. 62/944,292, titled “Large Scale Phenotypic Organoid Analysis” filed Dec. 5, 2019. [cited by applicant]
Wang, Z. et al. “Multiscale structural similarity for image quality assessment.” The Thrity-Seventh Asilomar Conference on Signals, Systems & Computers, 2003. vol. 2. Ieee, 2003. [cited by applicant]
Zhang, Z., et al. “Label-Free Estimation of Therapeutic Efficacy on 3D Cancer Spheres Using Convolutional Neural Network Image Analysis.” Analytical chemistry 91.21 (2019): 14093-14100. [cited by applicant]
Zhao, H., et al. “Loss functions for image restoration with neural networks.” IEEE Transactions on computational imaging 3.1 (2016): 47-57. [cited by applicant]
Zhao, H., et al. “Loss functions for neural networks for image processing.” arXiv preprint arXiv:1511.08861 (2015). [cited by applicant]